Cristina Fillat
Grup de recerca
- Teràpia gènica i càncer Group leader (R4)
Publicacions destacades
-
Codon Usage and Adenovirus Fitness: Implications for Vaccine Development
Autors:Referència: Frontiers In Microbiology 2021. -
Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses
Autors:Referència: Theranostics 2020. -
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth
Autors:Referència: Gut 2019. -
Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer.
Autors:Referència: Molecular Therapy 2019. -
Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies
Autors:Referència: Nature Communications 2017. -
AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-KB mediated uPAR activation
Autors:Referència: Molecular Cancer 2015. -
A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus
Autors:Referència: Journal Of Controlled Release 2014. -
MiR-148a-and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity
Autors:Referència: Molecular Therapy 2014. -
Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome
Autors:Referència: Neurobiology Of Disease 2013. -
Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome
Autors:Referència: American Journal Of Human Genetics 2008.
Projectes destacats
-
Immunological incompatibility as a basis for cancer curing and vaccination - ULISES
Investigador/a principal: Cristina Fillat FontsFinançador: European CommissionCodi: 899708Durada: 01/10/2020 - 02/10/2023 -
Adeno-associated viral gene therapy with AAV9-GCDH to correct glutaric aciduria type I in Gcdh -/- mice.
Investigador/a principal: Cristina Fillat FontsFinançador: Fundación Ramón ArecesCodi: CIVP19S8539Durada: 03/04/2019 - 30/09/2022 -
Adenovirus oncoliticos protegidos frente anticuerpos neutralizantes y optimizados para la expresion de transgenes y reprogramacion del estroma de tumores pancreaticos
Investigador/a principal: Cristina Fillat FontsFinançador: Ministerio de Economia y Competitividad (MINECO)Codi: BIO2017-89745-CR-2-RDurada: 01/01/2018 - 01/01/2020 -
Grup de Recerca Reconegut: teràpia gènica i neoplàsia pancreàtica
Investigador/a principal: Cristina Fillat FontsFinançador: Generalitat de CatalunyaCodi: 2017-SGR-00861Durada: 01/01/2017 - 30/09/2021